Scientists test First-Ever gene therapy to halt blindness
NCT ID NCT03374657
Summary
This is the first-ever human study of an experimental gene therapy called CPK850 for a rare, inherited form of vision loss called RLBP1 retinitis pigmentosa. The main goals are to find a safe dose and see if a single injection into the eye can help improve patients' vision, especially in low light. About 12 adult patients will be followed for five years after receiving the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Stockholm, SE-112 82, Sweden
Conditions
Explore the condition pages connected to this study.